Clinical and functional outcome of total hip arthroplasty in patients with acromegaly: mean twelve year follow-up.


Journal

International orthopaedics
ISSN: 1432-5195
Titre abrégé: Int Orthop
Pays: Germany
ID NLM: 7705431

Informations de publication

Date de publication:
08 2022
Historique:
received: 02 04 2022
accepted: 15 05 2022
pubmed: 22 5 2022
medline: 6 8 2022
entrez: 21 5 2022
Statut: ppublish

Résumé

Acromegaly is a rare and chronic hormonal disorder. Persons with acromegaly frequently live well into adulthood. Patients with active acromegaly have multiple joint-related issues; however, acromegalic arthropathy (AA), which is secondary osteoarthritis (OA), is considered one of the most common musculoskeletal complications of acromegaly. This study aims to analyze a cohort of patients who underwent total hip arthroplasty (THA) for AA at our institution and present the long-term clinical outcomes and causes of revision in these patients. All patients, who underwent total hip arthroplasty due to secondary osteoarthritis related to acromegaly between January 2001 and December 2019 at our institution, were included in this retrospective study. There were 15 patients (22 hips) with a mean follow-up of 12 years (range 4-20). Survivorship free of component revision was determined using Kaplan-Meier analysis. Patient-reported clinical outcomes were assessed using Harris Hip Scores. At the final follow-up, the status of the implant was known in all 15 hips. No patients were lost to follow-up. Five patients (9 hips) were deceased. Three hips (14%) underwent a revision surgery at a mean of six years (range 3-10). Survivorship free of component revision was 81% at 15 years. Mean Harris Hip Scores at final follow-up were fair (mean 64.3, range 32-91), but significantly improved compared to preoperative scores (p < 0.05). Acromegaly is a rare disorder that has direct effects on bone and joints. Our results suggest that THA can result in successful clinical and functional outcomes in patients with AA of the hip however the risk of aseptic loosening should also be considered in this patient population.

Identifiants

pubmed: 35597862
doi: 10.1007/s00264-022-05447-5
pii: 10.1007/s00264-022-05447-5
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1741-1747

Informations de copyright

© 2022. The Author(s) under exclusive licence to SICOT aisbl.

Références

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700
doi: 10.1210/jc.2014-2700 pubmed: 25356808
Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2:29–41. https://doi.org/10.1023/a:1009965803750
doi: 10.1023/a:1009965803750 pubmed: 11081170
Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N (2017) Epidemiology of acromegaly: review of population studies. Pituitary 20:4–9. https://doi.org/10.1007/s11102-016-0754-x
doi: 10.1007/s11102-016-0754-x pubmed: 27743174
Ruchala M, Wolinski K (2019) Health-related complications of acromegaly-risk of malignant neoplasms. Front Endocrinol (Lausanne) 10:268. https://doi.org/10.3389/fendo.2019.00268
doi: 10.3389/fendo.2019.00268
Ramos-Leví AM, Marazuela M (2019) Bringing cardiovascular comorbidities in acromegaly to an update. how should we diagnose and manage them? Front Endocrinol 10. https://doi.org/10.3389/fendo.2019.00120
Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426. https://doi.org/10.1210/jcem.83.10.5222
doi: 10.1210/jcem.83.10.5222 pubmed: 9768641
Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789–2796. https://doi.org/10.1210/jc.2003-032041
doi: 10.1210/jc.2003-032041 pubmed: 15181059
Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674. https://doi.org/10.1210/jc.2003-031199
doi: 10.1210/jc.2003-031199 pubmed: 14764779
Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, Dekkers OM, Sorensen HT, Jorgensen JO (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol 175:181–190. https://doi.org/10.1530/EJE-16-0117
doi: 10.1530/EJE-16-0117 pubmed: 27280374
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731–2739. https://doi.org/10.1210/jc.2004-2297
doi: 10.1210/jc.2004-2297 pubmed: 15741257
Wassenaar MJ, Biermasz NR, Kloppenburg M, van der Klaauw AA, Tiemensma J, Smit JW, Pereira AM, Roelfsema F, Kroon HM, Romijn JA (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res 20:226–233. https://doi.org/10.1016/j.ghir.2010.02.003
doi: 10.1016/j.ghir.2010.02.003 pubmed: 20194043
Wassenaar MJ, Biermasz NR, van Duinen N, van der Klaauw AA, Pereira AM, Roelfsema F, Smit JW, Kroon HM, Kloppenburg M, Romijn JA (2009) High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol 160:357–365. https://doi.org/10.1530/EJE-08-0845
doi: 10.1530/EJE-08-0845 pubmed: 19050166
Tornero J, Castaneda S, Vidal J, Herrero-Beaumont G (1990) Differences between radiographic abnormalities of acromegalic arthropathy and those of osteoarthritis. Arthritis Rheum 33:455–456. https://doi.org/10.1002/art.1780330332
doi: 10.1002/art.1780330332 pubmed: 2317234
Colao A, Pivonello R, Scarpa R, Vallone G, Ruosi C, Lombardi G (2005) The acromegalic arthropathy. J Endocrinol Invest 28:24–31
doi: 10.1007/BF03347225
Bluestone R, Bywaters EG, Hartog M, Holt PJ, Hyde S (1971) Acromegalic arthropathy. Ann Rheum Dis 30:243–258. https://doi.org/10.1136/ard.30.3.243
doi: 10.1136/ard.30.3.243 pubmed: 4253632 pmcid: 1005763
Killinger Z, Kuzma M, Sterancakova L, Payer J (2012) Osteoarticular changes in acromegaly. Int J Endocrinol 2012:839282. https://doi.org/10.1155/2012/839282
doi: 10.1155/2012/839282 pubmed: 23008710 pmcid: 3447355
Horta-Baas G (2021) Articular manifestations in acromegaly: diagnostic and therapeutic implications of the coexistence of acromegalic arthropathy and rheumatoid arthritis. An Sist Sanit Navar 44:97–105. https://doi.org/10.23938/ASSN.0928
doi: 10.23938/ASSN.0928 pubmed: 33853222
Biermasz NR, Wassenaar MJ, van der Klaauw AA, Pereira AM, Smit JW, Roelfsema F, Wolterbeek R, Kroon HM, Kloppenburg M, Romijn JA (2009) Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab 94:2374–2379. https://doi.org/10.1210/jc.2008-2393
doi: 10.1210/jc.2008-2393 pubmed: 19366851
Kurtz SM, Ong KL, Lau E, Widmer M, Maravic M, Gomez-Barrena E, de Pina MF, Manno V, Torre M, Walter WL, de Steiger R, Geesink RG, Peltola M, Roder C (2011) International survey of primary and revision total knee replacement. Int Orthop 35:1783–1789. https://doi.org/10.1007/s00264-011-1235-5
doi: 10.1007/s00264-011-1235-5 pubmed: 21404023 pmcid: 3224613
Sayers A, Steele F, Whitehouse MR, Price A, Ben-Shlomo Y, Blom AW (2020) Association between surgical volume and failure of primary total hip replacement in England and Wales: findings from a prospective national joint replacement register. BMJ Open 10:e033045. https://doi.org/10.1136/bmjopen-2019-033045
doi: 10.1136/bmjopen-2019-033045 pubmed: 32928843 pmcid: 7490953
Whittington MD, Munoz KA, Whalen JD, Ribeiro-Oliveira A, Campbell JD (2021) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res 59:101389. https://doi.org/10.1016/j.ghir.2021.101389
doi: 10.1016/j.ghir.2021.101389 pubmed: 34126556
Pelsma ICM, Biermasz NR, van Furth WR, Pereira AM, Kroon HM, Kloppenburg M, Claessen K (2021) Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. J Clin Endocrinol Metab 106:188–200. https://doi.org/10.1210/clinem/dgaa747
doi: 10.1210/clinem/dgaa747 pubmed: 33099640
Murray DW (1993) The definition and measurement of acetabular orientation. J Bone Joint Surg Br 75:228–232. https://doi.org/10.1302/0301-620X.75B2.8444942
doi: 10.1302/0301-620X.75B2.8444942 pubmed: 8444942
Engh CA Jr, Culpepper WJ 2nd, Engh CA (1997) Long-term results of use of the anatomic medullary locking prosthesis in total hip arthroplasty. J Bone Joint Surg Am 79:177–184
doi: 10.2106/00004623-199702000-00003
Engh CA, Bobyn JD, Glassman AH (1987) Porous-coated hip replacement. The factors governing bone ingrowth, stress shielding, and clinical results. J Bone Joint Surg Br 69:45–55. https://doi.org/10.1302/0301-620X.69B1.3818732
doi: 10.1302/0301-620X.69B1.3818732 pubmed: 3818732
Gruen TA, McNeice GM, Amstutz HC (1979) “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res 141:17–27
Prencipe N, Scarati M, Manetta T, Berton AM, Parisi S, Bona C, Parasiliti-Caprino M, Ditto MC, Gasco V, Fusaro E, Grottoli S (2020) Acromegaly and joint pain: is there something more? A cross-sectional study to evaluate rheumatic disorders in growth hormone secreting tumor patients. J Endocrinol Invest 43:1661–1667. https://doi.org/10.1007/s40618-020-01268-8
doi: 10.1007/s40618-020-01268-8 pubmed: 32333332
Melikoglu MA, Sezer I, Kocabas H, Akdag A, Balci N (2008) Acromegalic arthropathy of the hip: a case report. Acta Reumatol Port 33:357–359
pubmed: 18846016
Wassenaar MJ, Biermasz NR, Bijsterbosch J, Pereira AM, Meulenbelt I, Smit JW, Roelfsema F, Kroon HM, Romijn JA, Kloppenburg M (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70:320–325. https://doi.org/10.1136/ard.2010.131698
doi: 10.1136/ard.2010.131698 pubmed: 21131647
Claessen KM, Kloppenburg M, Kroon HM, Romijn JA, Pereira AM, Biermasz NR (2013) Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res 23:159–164. https://doi.org/10.1016/j.ghir.2013.05.003
doi: 10.1016/j.ghir.2013.05.003 pubmed: 23810124
Bennett GA (1972) Metabolic, degenerative and inflammatory diseases of bone and joints. JAMA J Am Med Assoc 222. https://doi.org/10.1001/jama.1972.03210080143038
Li G, Ma Y, Cheng TS, Landao-Bassonga E, Qin A, Pavlos NJ, Zhang C, Zheng Q, Zheng MH (2014) Identical subchondral bone microarchitecture pattern with increased bone resorption in rheumatoid arthritis as compared to osteoarthritis. Osteoarthritis Cartilage 22:2083–2092. https://doi.org/10.1016/j.joca.2014.08.015
doi: 10.1016/j.joca.2014.08.015 pubmed: 25205016
Johanson NA, Vigorita VJ, Goldman AB, Salvati EA (1983) Acromegalic arthropathy of the hip. Clin Orthop Relat Res 173:130–139
doi: 10.1097/00003086-198303000-00017
Chaouat D, Lambrozo J, Baffet A, Vignaud D (1984) Bilateral aseptic osteonecrosis of the femoral head in acromegaly. Rev Rhum Mal Osteoartic 51:215–217
pubmed: 6729381
Koulischer S, Kapanci B, Bloemers N, Charles T, Jayankura M (2017) Aseptic loosening after total hip arthroplasty in an acromegalic patient: a case report. J Orthop Case Rep 7:94–97. https://doi.org/10.13107/jocr.2250-0685.768
doi: 10.13107/jocr.2250-0685.768 pubmed: 28819613 pmcid: 5553848

Auteurs

Mustafa Akkaya (M)

Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany.
Department of Orthopaedics and Traumatology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

Antonio Pignataro (A)

Medical School of Università Degli Studi Gabriele D'Annunzio, Pescara, Italy.

Nemandra Sandiford (N)

Joint Reconstruction Unit, Southland Hospital, Invercargill, New Zealand.

Thorsten Gehrke (T)

Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany.

Mustafa Citak (M)

Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany. mcitak@gmx.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH